Results 31 to 40 of about 11,369 (213)
The Multifaceted Role of Macrophages in Oncolytic Virotherapy [PDF]
One of the cancer hallmarks is immune evasion mediated by the tumour microenvironment (TME). Oncolytic virotherapy is a form of immunotherapy based on the application of oncolytic viruses (OVs) that selectively replicate in and induce the death of tumour
Martine L. M. Lamfers +5 more
core +3 more sources
The Hitchhiker's Guide to Virotherapy
In contrast to most other cancer therapies, early research with oncolytic viruses (OV) tended to use direct or intratumoural routes of administration, initially motivated by concerns that the major limitation of intravenous delivery would be immune attack against the viruses, whether by complement, cytokine or most critically neutralising antibodies ...
Donnelly, O +4 more
openaire +5 more sources
Cytokines in oncolytic virotherapy
Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail ...
Pol, Jonathan +4 more
openaire +3 more sources
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect [PDF]
: With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits.
core +1 more source
The Role of the Innate Immune System in Oncolytic Virotherapy [PDF]
The complexity of the immune responses is a major challenge in current virotherapy. This study incorporates the innate immune response into our basic model for virotherapy and investigates how the innate immunity affects the outcome of virotherapy.
Tuan Anh Phan, Jianjun Paul Tian
core +1 more source
Personalized virotherapy in cancer
After decades of intensive research, pancreatic adenocarcinoma (PDAC) remains a highly lethal disease with a median survival time that does not exceed 6.5 months [1]. Since more than 80% of patients present with advanced metastatic disease, systemic chemotherapy remains the only treatment.
Cafferata Eduardo G +1 more
openaire +3 more sources
Oncolytic Virotherapy Trials—Letter [PDF]
We would like to thank Prof. Harrington for his insightful commentary ([1][1]) regarding our article by Kanerva and colleagues ([2][2]). During 2007–2011, the Advanced Therapy Access Program (ATAP) provided a unique opportunity for patients to access a technology they would not otherwise have ...
Hemminki Akseli +3 more
openaire +2 more sources
Diffuse alveolar hemorrhage (DAH) is one of the most serious clinical complications of systemic lupus erythematosus (SLE). The prevalence of DAH is reported to range from 1 to 5%, but while DAH is considered a rare complication there is a reported 50–80%
Qiuyun Guo +13 more
doaj +1 more source
Oncolytic Viruses and the Immune System: The Dynamic Duo
Oncolytic viruses (OVs) constitute a new and promising immunotherapeutic approach toward cancer treatment. This therapy takes advantage of the natural propensity of most tumor cells to be infected by specific OVs.
Ana Lemos de Matos +2 more
doaj +1 more source
Mathematical Models in Oncolytic Virotherapy and Immunology [PDF]
In this thesis we build mathematical models to address fundamental questions in immunology and virotherapy. We begin with a study of T cell response to pathogens.
Pooladvand, Pantea
core

